Ground-level proof points accumulating: management narrates several small, named, recent wins and treats them as the lea
The model's full reasoning — Q3 2016 call → NOThe question asks whether management's account rests on several small, concrete, ground-level wins that it names and describes individually, AND whether management explicitly treats these accumulating episodes as the leading edge of a broader improvement that is still early. Let me examine the transcript for specific episodes: 1. Margetuximab - Phase 3 SOPHIA trial - "approximately 90% of the anticipated trial sites have been activated in both the U.S. and Europe" - this is a specific operational milestone. 2. Margetuximab + pembrolizumab trial - "this program was recently approved to expand into the first of three Asian countries. We're specific in opening trial sites in Korea soon and believe approvals for Taiwan and Singapore will follow." 3. Enoblituzumab - "the combination study with pembrolizumab has advanced into dose expansion cohorts, while the enoblituzumab study is completing the last dose-escalation cohort." 4. MGA012 - "our IND for MGA012 an antibody being developed for the treatment of solid tumors cleared the FDA and we are working on start after the Phase 1 clinical trial." 5. MGD010 - "MacroGenics recently dealt the last subject in the final cohort of our Phase 1 study of MGD010." 6. MGD014 - "We expect to bid an IND for MGD014 in the first half of 2017." 7. MGD013 - "The other 2017 IND submission will be for MGD013" Now, are these "episodes" that actually happened recently? Some are: - 90% of trial sites activated (specific, recent) - Approval to expand into Korea (specific, recent) - Enoblituzumab combo advanced to dose expansion (specific, recent) - MGA012 IND cleared FDA (specific, recent) - MGD010 last subject dosed (specific, recent) These are indeed granular, specific, individually identifiable events. That's more than three. Now, does management connect these into a building pattern that is still early? Let me look for that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| TGI | Triumph Group, Inc. | Q2 2017 | 2016-11-03 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
AU · Q2 2018 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple specific, recent operational episodes: Kibali’s underground ramp-up with automated ore handling system and vertical shaft integration; Iduapriem’s CIL tank conversion and grade/tonnage gains; Sunrise Dam’s Recovery Enhancement Project plus new mining strategies; Tropicana’s second 6-MW ball mill installation; Siguiri’s CIL circuit milestone; and 338 tracked Operational Excellence projects.
BXP · Q1 2022 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...YES The transcript shows multiple distinct, named episodes from the recent period: the 73,000 sq ft recapture/release at 77 CityPoint with a 15% rent increase and 7.
CRGO · Q1 2024 → YESThe question is: Does management's account of the just-reported period rest on SEVERAL SMALL, CONCRETE, GROUND-LEVEL WINS THAT IT NAMES AND DESCRIBES INDIVIDUALLY — specific recent episodes from insid...